Dynavax Technologies (DVAX) Q3 2024 earnings summary

Executive summary

• HEPLISAV-B net product revenue reached $79.3M in Q3 2024, up 27% year-over-year, driving recurring profitability and transforming the business into a profitable company.

• Net income for Q3 2024 was $17.6M ($0.13 per share basic), compared to $14.3M in Q3 2023, supporting full-year profitability.

• Discontinued the Tdap-1018 program after Phase 1 results did not show a differentiated profile, reflecting disciplined pipeline management.

• Cash and marketable securities rose to $764M as of September 30, 2024, supporting pipeline development and external growth opportunities.

• Board authorized a $200M share repurchase program in November 2024 as part of capital allocation strategy.

Financial highlights

• Q3 2024 total revenues were $80.6M, with HEPLISAV-B accounting for $79.3M and other revenue at $1.3M.

• Gross margin improved to 84% in Q3 and 82% for the first nine months, exceeding full-year guidance of ~80%.

• Operating expenses totaled $70.5M, with R&D at $14.4M and SG&A at $43.1M, both increasing year-over-year.

• Cost of sales for HEPLISAV-B decreased due to lower per-unit manufacturing costs and fewer one-time charges.

• Cash and marketable securities increased to $764M from $742M at year-end 2023.

Outlook and guidance

• 2024 HEPLISAV-B net product revenue guidance narrowed to $265–$270M, with gross margin around 80%.

• R&D expenses projected at $55–$65M; SG&A at $170–$180M.

• Full-year profitability and positive net income anticipated for 2024.

• HEPLISAV-B market opportunity expected to exceed $900M by 2030, with at least 60% market share.

• Research and development expenses are expected to increase as the clinical pipeline advances.